Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luc Y Dirix

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|February 28, 2018
Adjuvant aromatase inhibition: more options for patientsLuc Y Dirix
The Lancet. Oncology|October 3, 2014
Bevacizumab beyond progression in breast cancerLuc Y Dirix, Andrew R Reynolds
The Lancet. Oncology|March 2, 2012
Inflammatory HER2-positive breast cancerLuc Y Dirix, Peter B Vermeulen
Lancet (London, England)|April 20, 2002
Gene-expression profiling to classify soft-tissue sarcomasLuc Y Dirix, Allan T van Oosterom
Cancer|July 9, 2004
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinomaRoberto Salgado, Peter Vermeulen, Luc Y Dirix
European Urology|July 1, 2019
Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51Piet R Dirix, Carole Mercier, Luc Y Dirix
Expert Opinion on Biological Therapy|March 13, 2013
Trastuzumab emtansine in breast cancerLuc Y Dirix, Annemie Rutten, Philippe Huget, et al.
Cancer|May 27, 2010
Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledgePeter B Vermeulen, Kenneth L van Golen, Luc Y Dirix
Methods in Molecular Biology (Clifton, N.J.)|April 7, 2009
cDNA microarray analysis of inflammatory breast cancer signaturesSteven J Van Laere, Peter B Vermeulen, Luc Y Dirix
Current Opinion in Oncology|September 22, 2006
Inflammatory breast cancer: current understandingLuc Y Dirix, Peter Van Dam, Annemie Prové, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|February 28, 2018
Adjuvant aromatase inhibition: more options for patientsLuc Y Dirix
The Lancet. Oncology|October 3, 2014
Bevacizumab beyond progression in breast cancerLuc Y Dirix, Andrew R Reynolds
The Lancet. Oncology|March 2, 2012
Inflammatory HER2-positive breast cancerLuc Y Dirix, Peter B Vermeulen
Lancet (London, England)|April 20, 2002
Gene-expression profiling to classify soft-tissue sarcomasLuc Y Dirix, Allan T van Oosterom
Cancer|July 9, 2004
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinomaRoberto Salgado, Peter Vermeulen, Luc Y Dirix
European Urology|July 1, 2019
Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51Piet R Dirix, Carole Mercier, Luc Y Dirix
Expert Opinion on Biological Therapy|March 13, 2013
Trastuzumab emtansine in breast cancerLuc Y Dirix, Annemie Rutten, Philippe Huget, et al.
Cancer|May 27, 2010
Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledgePeter B Vermeulen, Kenneth L van Golen, Luc Y Dirix
Methods in Molecular Biology (Clifton, N.J.)|April 7, 2009
cDNA microarray analysis of inflammatory breast cancer signaturesSteven J Van Laere, Peter B Vermeulen, Luc Y Dirix
Current Opinion in Oncology|September 22, 2006
Inflammatory breast cancer: current understandingLuc Y Dirix, Peter Van Dam, Annemie Prové, et al.
Pageof 9